Estrogen and Progestin, Lipoprotein(a), and the Risk of Recurrent Coronary Heart Disease Events After Menopause

Article Abstract:

Women with high lipoprotein(a) [Lp(a)] levels may benefit from estrogen/progestin treatment. Elevated blood levels of Lp(a) are a risk factor for coronary heart disease. In a study of 2,763 postmenopausal women with coronary heart disease, those with elevated Lp(a) levels were more likely to have chest pain or a heart attack. Estrogen and progestin treatment lowered Lp(a) levels compared to treatment with a placebo. This effect was most noticeable in women with very high levels of Lp(a).

Care and treatment, Coronary heart disease, Lipoprotein A

---

Effect of hysterectomy vs. medical treatment on health-related quality of life and sexual functioning: the medicine or surgery (Ms) randomized trial

Article Abstract:

Hysterectomy is a major surgical procedure carried out for non obstetric reasons more commonly in United States. The effect of hysterectomy is compared with expanded medical treatment on health-related quality of life.

United States, Women, Dosage and administration, Hysterectomy

---

Effects of hormone replacement therapy on endometrial histology in postmenopausal women: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial

Article Abstract:

Postmenopausal women who need to take estrogen replacement therapy should also take a progestin to prevent the development of endometrial hyperplasia. Endometrial hyperplasia can be a precursor to endometrial cancer. Researchers followed 596 postmenopausal women who were randomly assigned to take a daily placebo, estrogen alone, or one of three estrogen/progestin combinations. The women had annual endometrial biopsies and were followed for three years. At the end of the study, 85% of the women had normal biopsies. The incidence of endometrial hyperplasia was much higher in the women taking estrogen alone, while the incidence in women taking estrogen/progestin combinations was no higher than the incidence in women taking a placebo. Almost two-thirds of those taking estrogen alone developed hyperplasia. Eighty-six percent of all women with simple hyperplasia reverted to normal spontaneously or following treatment. Women taking estrogen alone accounted for 66% of unscheduled biopsies, 86% of D&Cs and 50% of hysterectomies.

Complications and side effects, Risk factors, Hormone therapy, Endometrial hyperplasia

Similar abstracts:

• Abstracts: Effect of Estrogen on Brain Activation Patterns in Postmenopausal Women During Working Memory Tasks. Estrogen and Alzheimer Disease Plausible Theory, Negative Clinical Trial
• Abstracts: The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women: Results From the MORE Randomized Trial
• Abstracts: Adherence to postmenopausal hormone therapy during the year after the initial prescription: a population-based study
• Abstracts: Patterns of congenital anomalies and relationship to initial maternal fasting glucose levels in pregnancies complicated by type 2 and gestational diabetes
• Abstracts: Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.